When repeated biopsy dramatically changes treatment tactics in metastatic castration-refractory prostate cancer with neuroendocrine transformation: clinical case and literature review
https://doi.org/10.17650/1726-9776-2024-20-2-122-128
Abstract
Neuroendocrine neoplasia of the prostate gland is a rather rare neuroendocrine carcinoma characterized by poor prognosis. With an atypical course of prostate adenocarcinoma in certain cases, it is possible to suspect development of secondary neuroendocrine cancer. A timely repeat biopsy and correct diagnosis can affect both the patient’s life expectancy and his quality of life.
About the Authors
I. S. Usoltseva
Sakhalin Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Inessa Stanislavovna Usoltseva
3 Gorky St., Yuzhno-Sakhalinsk 693010
E. L. Parsadanova
Sakhalin Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
3 Gorky St., Yuzhno-Sakhalinsk 693010
Yu. K. Kim
Sakhalin Regional Pathologoanatomical Bureau
Russian Federation
Russian Federation
430 Mira Prospekt, Yuzhno-Sakhalinsk 693004
References
1. Abbas F., Civantos F., Benedetto P., Soloway M.S. Small cell carcinoma of the bladder and prostate. Urology 1995;46(5):617–30. DOI: 10.1016/S0090-4295(99)80290-8
2. Cohen R.J., Glezerson G., Taylor L.F. et al. The neuroendocrine cell population of the human prostate gland. J Urol 1993;150(2 Pt 1): 365–8. DOI: 10.1016/s0022-5347(17)35484-8
3. Abbasova D.V., Polikarpova S.B., Kozlov N.A. et al. Neuroendocrine carcinoma of the prostate (review of the literature). Sovremennaya onkologiya = Journal of Modern Oncology 2019;21(3):52–5. (In Russ.). DOI: 10.26442/18151434.2019.3.190673
4. Frank G.A., Andreeva Yu.Yu., Moskvina L.V. et al. A new WHO classification of prostate tumors. Arkhiv patologii = Russian Journal of Archive of Pathology 2016;78(4):32–42. (In Russ.) DOI: 10.17116/patol201678432-42
5. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet 1967;124(5):1011–7.
6. Gilani S., Guo C.C., Li-Ning E.M. et al. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment. Hum Pathol 2017;64:186–90. DOI: 10.1016/j.humpath.2017.01.006
7. Terry S., Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 2014;4:60. DOI: 10.3389/fonc.2014.00060
8. Priemer D.S., Montironi R., Wang L. et al. Neuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization Classifcation. Endocr Pathol 2016;27(2):123–35. DOI: 10.1007/s12022-016-9421-z
9. Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2023;13(3s2):640–60. DOI: 10.18027/2224-5057-2023-13-3s2-1-640-660
10. Nosov D.A., Volkova M.I., Gladkov O.A. et al. Practical guidelines on treatment of prostate cancer. Zlokachestvennie opukholi: Prakticheskie rekomendatsii RUSSCO = Malignant Tumors: RUSSCO Practical Guidelines 2023;13(3s2):640–60. (In Russ.). DOI: 10.18027/2224-5057-2023-13-3s2-1-640-660
11. Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Oncol 2018;36(24):2492–503. DOI: 10.1200/JCO.2017.77.6880
12.
13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate cancer. Version 4.2023. Available at: https://www.nccn.org/professionals/ physician_gls/pdf/prostate.pdf
14. Loriot Y., Massard C., Gross-Goupil M. et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20(4):703–8. DOI: 10.1093/annonc/mdn694
15. Fléchon A., Pouessel D., Ferlay C. et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22(11):2476–81. DOI: 10.1093/annonc/mdr004
16. Caubet M., Dobi E., Pozet A. et al. Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study. Mol Clin Oncol 2015;3(6):1208–12. DOI: 10.3892/mco.2015.628
17. Corn P.G., Heath E.I., Zurita A. et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol 2019;20(10):1432–43. DOI: 10.1016/S1470-2045(19)30408-5
18. Briasoulis E., Aravantinos G., Kouvatseas G. et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 2013;13:263. DOI: 10.1186/1471-2407-13-263
19. De Bono J.S., Molife L.R., Sonpavde G. et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castrationresistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012;23(5):1241–9. DOI: 10.1093/annonc/mdr380
20. Michaelson M.D., Bellmunt J., Hudes G.R. et al. Multicenter phase II study of trabectedin in patients with metastatic castrationresistant prostate cancer. Ann Oncol 2012;23(5):1234–40. DOI: 10.1093/annonc/mdr399
21. Yashi M., Nishihara D., Mizuno T. et al. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castrationresistant prostate cancer: a prospective analysis of consecutive cases. Clin Genitourin Cancer 2014;12(5):e197–203. DOI: 10.1016/j.clgc.2014.02.007
22. Aparicio A.M., Harzstark A.L., Corn P.G. et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19(13):3621–30. DOI: 10.1158/1078-0432.CCR-12-3791
Review
For citations:
Usoltseva I.S., Parsadanova E.L., Kim Yu.K. When repeated biopsy dramatically changes treatment tactics in metastatic castration-refractory prostate cancer with neuroendocrine transformation: clinical case and literature review. Cancer Urology. 2024;20(2):122-128. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-2-122-128
Views:
209
Email this article 